{"groups":[{"description":"Belinostat 1000mg/m\\^2 administered as a 30 minute IV infusion from Days 1-5 of a 3-week cycle until disease progression or unmanageable treatment-related toxicities.","id":"FG000","title":"Belinostat"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"129"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"129"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with relapsed or refractory T-Cell lymphoma who signed the informed consent form and met all Inclusion/Exclusion criteria were enrolled in the study."}